MaxCyte (NASDAQ:MXCT – Get Free Report) and VivoSim Labs (NASDAQ:VIVS – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for MaxCyte and VivoSim Labs, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MaxCyte | 1 | 1 | 1 | 0 | 2.00 |
| VivoSim Labs | 1 | 0 | 0 | 0 | 1.00 |
MaxCyte currently has a consensus price target of $4.50, suggesting a potential upside of 278.15%. Given MaxCyte’s stronger consensus rating and higher probable upside, equities research analysts clearly believe MaxCyte is more favorable than VivoSim Labs.
Insider and Institutional Ownership
68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by insiders. Comparatively, 1.0% of VivoSim Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares MaxCyte and VivoSim Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MaxCyte | -81.40% | -15.05% | -12.79% |
| VivoSim Labs | -7,605.93% | -3,092.77% | -169.32% |
Risk and Volatility
MaxCyte has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.
Earnings & Valuation
This table compares MaxCyte and VivoSim Labs”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MaxCyte | $33.03 million | 3.72 | -$44.63 million | ($0.26) | -4.58 |
| VivoSim Labs | $112,000.00 | 18.82 | -$13.84 million | ($3.52) | -0.04 |
VivoSim Labs has lower revenue, but higher earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.
Summary
MaxCyte beats VivoSim Labs on 10 of the 14 factors compared between the two stocks.
About MaxCyte
MaxCyte, Inc. develops and commercializes cell-engineering technology used by biotechnology and pharmaceutical companies, academic research institutions, and cell therapy developers. Its platform is designed to introduce molecules such as DNA, RNA, and proteins into cells while maintaining cell viability, supporting applications in cell therapy, gene editing, and drug discovery. The company’s offerings include its Flow Electroporation systems, related consumables, and services. MaxCyte also works with cell therapy developers through licensing agreements that allow them to use its technology in developing and manufacturing therapeutic products.
About VivoSim Labs
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
